These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37131012)

  • 61. Increased risk for aseptic meningitis after amoxicillin or amoxicillin-clavulanic acid in males: A signal revealed by subset disproportionality analysis within a global database of suspected adverse drug reactions.
    Chandler RE
    Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):389-395. PubMed ID: 30556617
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety concerns reported by consumers, manufacturers and healthcare professionals: A detailed evaluation of opioid-related adverse drug reactions in the FDA database over 15 years.
    Andreaggi CA; Novak EA; Mirabile ME; Sampathkumar S; Gray MP; He M; Kane-Gill SL
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1627-1635. PubMed ID: 32851782
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases.
    Khouri C; Petit C; Tod M; Lepelley M; Revol B; Roustit M; Cracowski JL
    J Clin Epidemiol; 2021 Jun; 134():14-21. PubMed ID: 33508405
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases.
    Schifano N; Capogrosso P; Boeri L; Fallara G; Chiappini S; Rewhorn M; Cakir OO; Harvey H; Castiglione F; Alnajjar HM; Muneer A; Deho' F; Schifano F; Montorsi F; Salonia A
    Int J Impot Res; 2023 Aug; 35(5):465-471. PubMed ID: 35513712
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS).
    Chiappini S; Vickers-Smith R; Guirguis A; Corkery JM; Martinotti G; Harris DR; Schifano F
    Pharmaceuticals (Basel); 2022 May; 15(6):. PubMed ID: 35745593
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis.
    Gu T; Jiang A; Zhou C; Lin A; Cheng Q; Liu Z; Zhang J; Luo P
    Int J Cancer; 2023 Feb; 152(3):480-495. PubMed ID: 36274626
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions.
    Li Y; Jimeno Yepes A; Xiao C
    Drug Saf; 2020 Sep; 43(9):893-903. PubMed ID: 32385840
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases.
    Seabroke S; Candore G; Juhlin K; Quarcoo N; Wisniewski A; Arani R; Painter J; Tregunno P; Norén GN; Slattery J
    Drug Saf; 2016 Apr; 39(4):355-64. PubMed ID: 26748507
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012.
    Farcas A; Balcescu T; Anghel L; Bucsa C; Mogoșan C
    Expert Opin Drug Saf; 2020 Jun; 19(6):755-762. PubMed ID: 32186202
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Vestergaard Kvist A; Faruque J; Vallejo-Yagüe E; Weiler S; Winter EM; Burden AM
    J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33924496
    [No Abstract]   [Full Text] [Related]  

  • 72. Safety of antipsychotic drugs: A systematic review of disproportionality analysis studies.
    Cepaityte D; Siafis S; Papazisis G
    Behav Brain Res; 2021 Apr; 404():113168. PubMed ID: 33581145
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
    Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Qualitative Study of General Public Views towards Adverse Drug Reactions in Lithuania.
    Valinciute-Jankauskiene A; Loreta K
    Healthcare (Basel); 2021 Mar; 9(3):. PubMed ID: 33803215
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.
    Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD
    Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
    Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
    Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.